Invivyd, Inc. (IVVD): Total Assets
$276.88M
As of 2025-12-31
$218.88M
As of 2026-06-30
-10.3%
3-year compound annual growth
+18.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $276.88M | +113.8% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $129.51M | -43.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $229.18M | -40.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $383.17M | -38.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $620.09M | +428.3% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $117.38M | n/a | 2022-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
Compare IVVD, PLX, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗